Patient-Reported Outcomes in the QuANTUM-First Trial: Quizartinib Versus Standard Chemotherapy in FLT3-ITD AML patients

At the ASH meeting, Professor Oliva presented the patient-reported outcomes from the QuANTUM-First trial, a phase 3 clinical investigation assessing the efficacy and safety of quizartinib. Quizartinib, is approved in the US, Europe, and Japan for concurrent use with chemotherapy in the induction, consolidation phase and maintenance monotherapy for adults with newly diagnosed FLT3-ITD positive AML. Quizartinib demonstrated a clinical benefit over placebo, yielding a 17-month increase in OS as the primary endpoint.

Patient-reported outcomes on QoL were evaluated using the EORTC QLQ-C30 and EuroQol EQ-5D-5L instruments. Baseline measurements were collected on day 8 of the first induction cycle and compared to measurements at specific intervals throughout induction, consolidation, and continuation cycles.

For patients receiving quizartinib, a clinically significant improvement in QoL was observed post-induction and consolidation, persisting during the continuation phase. No statistical differences were noted between treatment arms for QoL and TUDD measurements.

In summary, the findings suggest that quizartinib treatment does not induce short- or long-term detrimental effects on QoL compared to placebo while demonstrating a clear benefit in OS, making it one of the best therapeutic choices for FLT3-ITD AML patients receiving induction chemotherapy.

Reference:

Oliva E,Patient-Reported Outcomes in Acute Myeloid Leukemia Patients with FLT3-ITD Mutation Receiving Quizartinib Vs. Standard Chemotherapy: Results from the Quantum-First Trial. ASH2023. #918

With the educational support of: